Compare EPOW & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPOW | TXMD |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 24.4M |
| IPO Year | 2019 | 2012 |
| Metric | EPOW | TXMD |
|---|---|---|
| Price | $0.55 | $1.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 119.4K | 49.6K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $201.00 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.53 | $0.99 |
| 52 Week High | $1.86 | $2.95 |
| Indicator | EPOW | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.96 | 43.67 |
| Support Level | N/A | $1.90 |
| Resistance Level | $0.73 | $2.09 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 2.60 | 4.65 |
E Power Inc, through its subsidiaries, is engaged in the manufacturing and sale of graphite anode material for lithium-ion batteries. It operates a plant in Guizhou Province, China, powered by electricity from renewable sources, which contributes to the plant's low production costs and reduced environmental impact in the production of graphite anode materials. Additionally, the Group also operates a knowledge-sharing platform business. Its reportable operating segments are: Graphite anode business, which generates the maximum revenue, and Knowledge sharing and enterprise business. Substantially all of the Group's revenue is derived in the People's Republic of China (the PRC).
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.